The study evaluates the effects of the Bushen Huatan (BSHT) formula on a non-obese PCOS rat model induced by letrozole, high-fat/high-sucrose diet, and a PEPD inhibitor over 35 days, followed by 28 days of treatment with assessments including OGTT, sex steroids, and lipid panels. BSHT administration reduced serum testosterone and increased estradiol (E2) and FSH, with improved glucose tolerance and a more favorable lipid profile (decreased total cholesterol and triglycerides, increased HDL-C).
Ovarian morphology showed attenuation of polycystic features, and hepatic lipid accumulation was decreased. Adipose-derived exosomes were characterized for size, concentration, and surface markers.
BSHT decreased adipose tissue–derived exosomal microRNA-27a-3p (AT-EXO-miR-27a-3p) expression and reduced Pparg mRNA levels, while markedly increasing insulin receptor (INSR) protein abundance in ovarian tissue. Ovarian PPARG, P-AKT, GLUT4, INSR, and IRS-1 were quantified, with notable post-treatment changes.
The data suggest BSHT may alleviate reproductive endocrine disturbances in PCOS by mitigating the inhibitory effect of fat-derived exosomal miR-27a-3p on PPARG; however, exact mechanisms and translational relevance require further clarification given model limitations.
PubMed / NCBI published a clinical update in Oncology on 09 Apr 2026.
The item focuses on Bushen Huatan formula improves reproductive and endocrine metabolic disorders in non-obese polycystic ovary syndrome rats via adipose tissue-derived exosomal miR-27a-3p/PPARG signaling pathway.
Review the original article for the full source wording and details.